Literature DB >> 24831679

[Etiopathogenesis of chronic inflammatory bowel diseases. Role of the immune system].

B Siegmund1.   

Abstract

The challenge of the mucosal immune system is to develop tolerance toward intestinal antigens. Considering the quantity of bacteria that continuously attack the intestinal barrier, one can only imagine the complexity involved. To master this task, a tight network between the intestinal microbiota, the barrier, immune cells of the lamina propria as well as the adjacent mesenteric fat tissue is required. The key pathways involved have been revealed by the genome-wide association studies as well as functional data from experimental models. However, although knowledge with regard to the pathogenesis of chronic inflammatory bowel disease has been increasing continuously over recent decades, the current therapeutic strategies are limited to controlling the pro-inflammatory effector phase rather than achieving cure. The best example is cytokine neutralizing antibodies. The present review aims to describe the role of the various cell populations within the intestinal wall for disease pathogenesis and, thus, identify possible therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831679     DOI: 10.1007/s00108-013-3440-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  49 in total

1.  Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities.

Authors:  P D Smith; L E Smythies; M Mosteller-Barnum; D A Sibley; M W Russell; M Merger; M T Sellers; J M Orenstein; T Shimada; M F Graham; H Kubagawa
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

2.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

3.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

Authors:  Jan Wehkamp; Nita H Salzman; Edith Porter; Sabine Nuding; Michael Weichenthal; Robert E Petras; Bo Shen; Elke Schaeffeler; Matthias Schwab; Rose Linzmeier; Ryan W Feathers; Hiutung Chu; Heriberto Lima; Klaus Fellermann; Tomas Ganz; Eduard F Stange; Charles L Bevins
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

5.  Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis.

Authors:  Andrey A Kruglov; Sergei I Grivennikov; Dmitry V Kuprash; Caroline Winsauer; Sandra Prepens; Gitta Maria Seleznik; Gerard Eberl; Dan R Littman; Mathias Heikenwalder; Alexei V Tumanov; Sergei A Nedospasov
Journal:  Science       Date:  2013-12-06       Impact factor: 47.728

6.  Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells.

Authors:  J Rodrigo Mora; Maria Rosa Bono; N Manjunath; Wolfgang Weninger; Lois L Cavanagh; Mario Rosemblatt; Ulrich H Von Andrian
Journal:  Nature       Date:  2003-07-03       Impact factor: 49.962

7.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

9.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

10.  Interleukin-23 drives intestinal inflammation through direct activity on T cells.

Authors:  Philip P Ahern; Chris Schiering; Sofia Buonocore; Mandy J McGeachy; Dan J Cua; Kevin J Maloy; Fiona Powrie
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

View more
  1 in total

1.  Shen-Ling-Bai-Zhu-San for ulcerative colitis: Protocol for a systematic review and meta-analysis.

Authors:  Long Yang; Yuanyuan Song; Pei Jin; Yueyang Liu; Yue Wang; Huixia Qiao; Yahui Huang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.